CA2730215A1 - Identifying cancers sensitive to treatment with inhibitors of notch signaling - Google Patents
Identifying cancers sensitive to treatment with inhibitors of notch signaling Download PDFInfo
- Publication number
- CA2730215A1 CA2730215A1 CA2730215A CA2730215A CA2730215A1 CA 2730215 A1 CA2730215 A1 CA 2730215A1 CA 2730215 A CA2730215 A CA 2730215A CA 2730215 A CA2730215 A CA 2730215A CA 2730215 A1 CA2730215 A1 CA 2730215A1
- Authority
- CA
- Canada
- Prior art keywords
- heyl
- notch
- level
- gene expression
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010070047 Notch Receptors Proteins 0.000 title claims abstract description 148
- 102000005650 Notch Receptors Human genes 0.000 title claims abstract description 148
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 109
- 239000003112 inhibitor Substances 0.000 title abstract description 21
- 230000011664 signaling Effects 0.000 title description 26
- 230000014509 gene expression Effects 0.000 claims abstract description 126
- 101150019344 Heyl gene Proteins 0.000 claims abstract description 67
- 230000004913 activation Effects 0.000 claims abstract description 48
- 201000011510 cancer Diseases 0.000 claims abstract description 42
- 210000001519 tissue Anatomy 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 36
- 230000035945 sensitivity Effects 0.000 claims abstract description 36
- 239000000523 sample Substances 0.000 claims description 27
- 108020004999 messenger RNA Proteins 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 18
- 238000002493 microarray Methods 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 238000003753 real-time PCR Methods 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 239000013068 control sample Substances 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 97
- 102100039993 Hairy/enhancer-of-split related with YRPW motif-like protein Human genes 0.000 description 69
- 101001035082 Homo sapiens Hairy/enhancer-of-split related with YRPW motif-like protein Proteins 0.000 description 69
- 108090000623 proteins and genes Proteins 0.000 description 36
- 230000005764 inhibitory process Effects 0.000 description 28
- 230000037361 pathway Effects 0.000 description 23
- 239000000090 biomarker Substances 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000001419 dependent effect Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 9
- 208000029742 colonic neoplasm Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 8
- 208000005017 glioblastoma Diseases 0.000 description 8
- 238000012417 linear regression Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 239000000092 prognostic biomarker Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000000107 tumor biomarker Substances 0.000 description 6
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003540 gamma secretase inhibitor Substances 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 102100036462 Delta-like protein 1 Human genes 0.000 description 3
- 102100036466 Delta-like protein 3 Human genes 0.000 description 3
- 102100033553 Delta-like protein 4 Human genes 0.000 description 3
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 description 3
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 3
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 208000010572 basal-like breast carcinoma Diseases 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229940127276 delta-like ligand 3 Drugs 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 102000046701 nicastrin Human genes 0.000 description 3
- 108700022821 nicastrin Proteins 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 238000010599 BrdU assay Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 101100506443 Danio rerio helt gene Proteins 0.000 description 2
- 102100026662 Delta and Notch-like epidermal growth factor-related receptor Human genes 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101001054266 Homo sapiens Delta and Notch-like epidermal growth factor-related receptor Proteins 0.000 description 2
- 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 description 2
- 101000994434 Homo sapiens Protein jagged-2 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100506445 Mus musculus Helt gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229940122315 Notch pathway inhibitor Drugs 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102100032702 Protein jagged-1 Human genes 0.000 description 2
- 102100032733 Protein jagged-2 Human genes 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 102000036664 ADAM10 Human genes 0.000 description 1
- 108091007504 ADAM10 Proteins 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 101100538048 Colletotrichum orbiculare (strain 104-T / ATCC 96160 / CBS 514.97 / LARS 414 / MAFF 240422) TRM8 gene Proteins 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
- 102100028260 Gamma-secretase subunit PEN-2 Human genes 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101150074178 HNT2 gene Proteins 0.000 description 1
- 101000579663 Homo sapiens Gamma-secretase subunit PEN-2 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 101150056261 Jag2 gene Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 101150057903 NRARP gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940121773 Secretase inhibitor Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 101150089041 aph-1 gene Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 101150042537 dld1 gene Proteins 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001861 endoscopic biopsy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000011773 genetically engineered mouse model Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000007386 incisional biopsy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007389 shave biopsy Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- -1 such as Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8012208P | 2008-07-11 | 2008-07-11 | |
| US61/080,122 | 2008-07-11 | ||
| US12/360,790 US7544476B1 (en) | 2008-07-11 | 2009-01-27 | Identifying cancers sensitive to treatment with inhibitors of notch signaling |
| US12/360,790 | 2009-01-27 | ||
| PCT/US2009/045479 WO2010005644A1 (en) | 2008-07-11 | 2009-05-28 | Identifying cancers sensitive to treatment with inhibitors of notch signaling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2730215A1 true CA2730215A1 (en) | 2010-01-14 |
Family
ID=40688675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2730215A Abandoned CA2730215A1 (en) | 2008-07-11 | 2009-05-28 | Identifying cancers sensitive to treatment with inhibitors of notch signaling |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7544476B1 (enExample) |
| EP (1) | EP2313526A4 (enExample) |
| JP (1) | JP2011527575A (enExample) |
| AU (1) | AU2009269081A1 (enExample) |
| CA (1) | CA2730215A1 (enExample) |
| WO (1) | WO2010005644A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007136856A2 (en) * | 2006-05-19 | 2007-11-29 | The Johns Hopkins University | Heyl as a therapeutic target and a diagnostic marker for neoplasia and uses therefor |
| WO2008076960A2 (en) | 2006-12-18 | 2008-06-26 | Genentech, Inc. | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| DK2935330T3 (da) | 2012-12-19 | 2019-07-22 | Aveo Pharmaceuticals Inc | Anti-notch3-antistoffer |
| EP3448420B1 (en) | 2016-04-29 | 2022-09-14 | Aveo Pharmaceuticals, Inc. | Anti-notch3 antibody |
| EP3462349A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of notch cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047878A1 (en) | 2004-11-03 | 2006-05-11 | British Columbia Cancer Agency Branch | Cancer therapeutics and methods for their use |
| CA2600908A1 (en) | 2005-03-04 | 2006-09-08 | The Hospital For Sick Children | Methods for cancer prognosis |
| DK1962895T3 (da) * | 2005-12-16 | 2013-03-04 | Regeneron Pharma | TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST |
| WO2007136856A2 (en) | 2006-05-19 | 2007-11-29 | The Johns Hopkins University | Heyl as a therapeutic target and a diagnostic marker for neoplasia and uses therefor |
-
2009
- 2009-01-27 US US12/360,790 patent/US7544476B1/en not_active Expired - Fee Related
- 2009-05-28 EP EP09794862A patent/EP2313526A4/en not_active Withdrawn
- 2009-05-28 JP JP2011517443A patent/JP2011527575A/ja active Pending
- 2009-05-28 WO PCT/US2009/045479 patent/WO2010005644A1/en not_active Ceased
- 2009-05-28 AU AU2009269081A patent/AU2009269081A1/en not_active Abandoned
- 2009-05-28 CA CA2730215A patent/CA2730215A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009269081A1 (en) | 2010-01-14 |
| JP2011527575A (ja) | 2011-11-04 |
| EP2313526A4 (en) | 2011-08-31 |
| EP2313526A1 (en) | 2011-04-27 |
| WO2010005644A1 (en) | 2010-01-14 |
| US7544476B1 (en) | 2009-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3115469B1 (en) | Lung cancer markers and uses thereof | |
| AU2013226323B2 (en) | Cancer patient selection for administration of Wnt signaling inhibitors using RNF43 mutation status | |
| US9846162B2 (en) | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer | |
| US7544476B1 (en) | Identifying cancers sensitive to treatment with inhibitors of notch signaling | |
| US20120177641A1 (en) | Gefitnib Sensitivity-Related Gene Expression and Products and Methods Related Thereto | |
| Massi et al. | Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients | |
| RU2651469C1 (ru) | Лечение рака | |
| JP2013508679A (ja) | チボザニブ応答の予測 | |
| Li et al. | Liquid biopsy by analysis of circulating myeloma cells and cell-free nucleic acids: a novel noninvasive approach of disease evaluation in multiple myeloma | |
| EP3724357B1 (en) | New onco-immunologic prognostic and theranostic markers | |
| US8747867B2 (en) | Cancer markers | |
| WO2012112645A1 (en) | Markers for identifying breast cancer treatment modalities | |
| JP6858563B2 (ja) | Ｂｒａｆ変異検出によるｅｇｆｒ阻害剤の効果予測 | |
| EP2542692B1 (en) | Method for selecting patients for treatment with an egfr inhibitor | |
| JP2009531065A (ja) | エストロゲン受容体アルファのメチル化、およびその使用 | |
| US10480032B2 (en) | Use of EI24 gene | |
| US20090004658A1 (en) | Integrin alpha 7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma | |
| KR20240023045A (ko) | 암 치료를 위한 진단 방법 및 조성물 | |
| HK1199744B (en) | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status | |
| HK1200530B (en) | Predicting tumor response to anti-erbb3 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20150528 |